Related Experiment Video
Updated: May 20, 2026
Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
Published on: November 10, 2023
Comparative proteome analysis of acute myeloid leukemia with and without maturation
Magdalena Luczak1, Maciej Kaźmierczak, Luiza Handschuh
1Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704 Poznan, Poland.
Abstract:
Acute myeloid leukemia (AML) is a severe, rapidly progressing disease triggered by blocking granulocyte or monocyte differentiation and maturation. Because of its heterogeneity, AML is divided into a number of subtypes. Unfortunately, so far very few correlations have been found between AML classification and its clinical course or patient response to treatment. In addition, as yet only a few subtype-specific AML biomarkers have been discovered. To solve these problems here, we focused on two AML subtypes M1 and M2 that are especially difficult to differentiate. Using 2D electrophoresis and mass spectrometry, we analyzed the protein profiles of peripheral blood (PB) and/or bone marrow (BM) samples collected from 38 AML-M1/M2 patients and 17 healthy volunteers. Comparative analysis of AML-M1/M2 and control PB/BM cells revealed 25 proteins that accumulated differentially. Hierarchical clustering of proteomic results clearly divided the AML samples into 2 groups (M1 and M2). Annexin III, L-plastin and 6-phosphogluconate dehydrogenase were found only in the M2 group. We also observed that the levels of annexin I and actin gamma 1 were correlated with resistance to treatment and the time of relapse. It appears that these five proteins can serve as potential AML biomarkers.
Insights
Researchers identified five proteins as potential biomarkers for acute myeloid leukemia (AML) subtypes M1 and M2. These findings could improve AML classification and treatment strategies for this aggressive blood cancer.
Area of Science:
- Proteomics
- Biochemistry
- Hematology
Background:
- Acute myeloid leukemia (AML) is a heterogeneous blood cancer characterized by blocked myeloid cell differentiation.
- Current AML classification lacks strong correlations with clinical outcomes, and subtype-specific biomarkers are scarce.
- Differentiating AML subtypes M1 and M2 presents a significant clinical challenge.
Purpose of the Study:
- To identify novel protein biomarkers for distinguishing between AML subtypes M1 and M2.
- To explore potential correlations between protein expression levels and treatment resistance or relapse in AML patients.
Main Methods:
- Proteomic analysis using 2D electrophoresis and mass spectrometry.
- Analysis of peripheral blood (PB) and/or bone marrow (BM) samples from 38 AML-M1/M2 patients and 17 healthy controls.
- Comparative analysis to identify differentially accumulating proteins and hierarchical clustering for sample classification.
Main Results:
- Twenty-five proteins showed differential accumulation between AML-M1/M2 and control samples.
- Hierarchical clustering successfully separated AML samples into M1 and M2 groups.
- Annexin III, L-plastin, and 6-phosphogluconate dehydrogenase were specific to the M2 subtype; Annexin I and actin gamma 1 levels correlated with treatment resistance and relapse.
Conclusions:
- Five proteins (Annexin III, L-plastin, 6-phosphogluconate dehydrogenase, Annexin I, and actin gamma 1) show potential as biomarkers for AML subtypes M1 and M2.
- These identified proteins may aid in differentiating AML subtypes and predicting treatment response.
- Further validation is needed to establish these proteins as reliable clinical biomarkers for acute myeloid leukemia.
